Neuroplast completed its preclinical program for Traumatic Spinal Cord Injury, ALS and Frontotemporal Dementia. In these preclinical Proof-of-Concept studies, the following general and therapeutic-specific observations were made:

 

General

• Not any sign of toxicity and/or other safety issues could be found.        

• All studies evidence for anti-inflammatory effects due to modification of pro-inflammatory cytokines observed.

 

Traumatic Spinal Cord Injury (TSCI)

• Significant improvement in locomotion in SCI lesioned rodents compared to vehicle.

• Mode of action anti-inflammatory, significantly stronger than methyl-prednisolone.

 

Amyotrophic Lateral Sclerosis

• Significant decrease in deterioration as compared to vehicle and riluzole treated FUS-TG mice.

 

Frontotemporal Dementia

• Significantly higher cognitive functioning as compared to vehicle treated FUS-TG mice expressing frontal temporal dementia.

​

In collaboration with: University of Tampere, Trium Clinical Consulting, Université Lille Nord de France, Universiteit Hasselt, Universität Würzburg, Maastricht UMC+, University of Oxford.